慢性髓性白血病完全细胞遗传学缓解后与伊马替尼相关的骨髓再生障碍
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
作者信息
Khan Khurshid Ahmed, Junaid Ayesha, Siddiqui Nauman Saleem, Mukhtar Khalida, Siddiqui Saleem
机构信息
Department of Oncology, National Oncology Research Institute, Islamabad.
出版信息
J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.
PMID:18460249
Abstract
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
摘要
甲磺酸伊马替尼是一种用于治疗慢性粒细胞白血病的BCR-ABL酪氨酸激酶抑制剂。它是一种安全且耐受性良好的药物，副作用较少且易于控制。我们报告了一例在完全细胞遗传学缓解后发生的与伊马替尼相关的致命性骨髓再生障碍病例。
Zotero 插件